Hepatitis C virus infection: Are there still specific problems with genotype 3?

Table 3 Overview of direct-acting antiviral-containing treatments for hepatitis C virus genotype-3-infected patients

Drug combination	Recommendations1	Duration	Ref.
IFN-containing treatment
PEG-IFN/RBV and SOF	For treatment-experienced patients, with or without cirrhosis	12 wk	[97]
PEG-IFN/RBV and DCV	Not yet recommended	12 or 16 wk	[98]
IFN-free treatment
SOF and RBV	Suboptimal in treatment-experienced cirrhotic patients	24 wk	[99,100]
SOF and DCV	For patients without cirrhosis	12 wk	[101]
SOF/DCV and RBV	For treatment-naive and treatment-experienced patients with cirrhosis	24 wk	[102]
SOF/ledipasvir (single-tablet regimen)	Not yet recommended	12 wk	[104]
Promising therapeutic option
GS-5816/SOF ± RBV	Under evaluation	12 wk	[107,108]

¹According to the EASL Clinical Practice Guidelines in April 2015[10].